The US Food & Drug Administration is facing a most unusual leadership transition with Acting Commissioner Janet Woodcock seemingly undergoing an informal tryout period that could end with her becoming the first career FDA official to be made commissioner since before the Nixon Administration.
Or the apparent opposition to her selection from some Senate Democrats could force the Biden Administration to start over and...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?